result solid context headwinds/comp agil face lasergen dilut
reduc ep though chang thesi agil still pois grow
revenue/ep peer expect upsid guidanc reduc p-t
ebitda due peer group multipl contract dcf could get us higher
revenu growth y/i line midpoint guidanc
publish sell side consensu expect said preview expect
upsid core growth develop caught us agil
surpris first icp-m revenu slip quarter second
reorgan chines food safeti ministri neg impact revenu
adjust develop core growth would y/i despit tough
comparison lunar new year time headwind
acg growth dgg growth ahead forecast
respect off-set lsag growth light forecast
end market pharma growth materi stronger expect
comparison howev chemic academ govern diagnost
modestli forecast notabl food declin due aforement
china chang geographi america europ revenu exceed
expect off-set asiapac came lighter expect china flat y/i
ep line model consensu rel model
lower expect interest expens ad ep gross margin
light expect fx dgg driver vs model partial off-set lower
expect oper spend drove oper margin increment
still light forecast
ye sens agil track record guid assumpt
may coupl develop dont go way said typic render
guidanc conserv wasnt case think like
case chang outlook china food growth food
total sale china food sale like depress full year growth
said still believ agil well posit drive core growth guidanc
also note guidanc growth level seem pretti
conserv icp-m revenu recaptur better comparison lunar new year time
dynam sens guidanc doesnt make ton sens expect upsid
pleas see page report import disclosur
continu view agil posit competit perspect continu
believ compani potenti gener signific margin expans next
sever year confid manag margin target believ could
room upsid look view guidanc rel conserv
clear potenti driver upsid seemingli littl downsid risk
top bottom line either buyer seller could drive upsid also
provid downsid protect like near long term outlook would await
attract entri point rate share market perform price target base
dcf analysi repres ev/ebitda
agil acquir larger
possibl addit
multipl group
organ growth oper margin
exceed
growth expect
lack growth render multipl high
growth lower expect
expect margin expans fail
life scienc diagnost chemic analysi compani
compani current oper segment life scienc appli market lsag
diagnost genom dgg agil crosslab group acg
margin expect lasergen look like could dilut
previous expect move forward aati off-set
yet reflect guidanc drove us reduc dgg margin expect
next year accordingli still see upsid ep expect
magnitud upsid may materi previous expect partial offset
lower interest expens previous expect
reduc revenu growth ep number howev driven
lasergen materi chang core agil expect accordingli thesi
agil chang expect agil grow faster peer top
bottom line forseeabl futur like post organ revenu growth
faster due nasd capac expans sustain doubl digit earn
growth lower price target due peer group multipl contract
repres ev/ebitda p/fcf dcf could get us higher
compani report thomson eikon cowen compani
cowen vs consensu mm except core fx core fx gross report adjust segment metric mm except growth growth growth statement mm except growth currenc line forecast expens forecast margin expect ad ep pre-tax per count gross margin came forecast consensu dgg greatest driver miss rel model fx also headwind quarter ep line model consensu high end guidanc exclud lower expect non-oper item ep would line high end lsag revenu came forecast core growth y/i forecast sever discret item impact growth includ china food ministri headwind icp-m shipment delay pull forward lunar new year revenu adjust alreadi known embed model underli core growth appear approxim lsag pharma chemical/energi primari growth driver robust perform develop acg revenu came better forecast core growth y/i better expect despit y/i headwind lunar new year time embed forecast accordingli underli basi acg grew y/i acg oper margin also better expect importantli acg grew doubl digit china dgg revenu came better expect core growth better model note dgg benefit custom settlement payment exclud dgg would grown underli basi clear settlement alreadi reflect model dgg oper margin oper margin adjust forecast rel model lower expect gross margin primari driver revenu came forecast core growth y/i forecast miss entir due lsag driven icp-m shipment delay alreadi book china food ministri reorgan headwind exclud alreadi known lunar new year core revenu growth would approxim y/i despit tough comparison lunar new year time accordingli pretti solid quarter cut discret item end market pharma grew acc/gov grew chemical/energi grew environment grew food declin cowen
compani report cowen compani
mm except per share datajan net net core re-affirmed fx avarian acq core fx currenc contribut adjust segmentlif scienc appli group currenc contribut adjust crosslab group currenc contribut adjust genom group currenc contribut adjust currenc currenc pacif growth china currenc end marketpharma growth growth growth re-affirmed growth growth total food biz chinareport growth cowen
compani report thomson eikon cowen compani
mm except per share datajan core re-affirmed fx aorgan core fx aconst gener oper oper report adjust non-oper incl keysight bill net interest net interest expens tax rate re-affirmed net earn per expectationsjan gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit macroeconom deterior
current level challeng china disrupt due keysight spin eros market
share price due competit inabl deliv incremental/decrement margin
target value-destruct
risk upsid includ limit greater expect organ revenu
growth and/or oper margin expans greater expect capit deploy
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc may et dissemin may et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
